NASDAQ: ME
23andme Holding Co Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ME stock forecasts and price targets.

Forecast return on equity

Is ME forecast to generate an efficient return?

Forecast return on assets

Is ME forecast to generate an efficient return on assets?

ME revenue forecast

What is ME's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$219.6M+13.63%
Avg 2 year Forecast
$260.0M+34.53%
ME's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ME revenue growth forecast

How is ME forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
15.99%
Industry
5.89%
Market
7.46%
ME's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ME's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ME vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
ME$3.61N/AN/A
NOTV$3.90$4.00+2.56%Strong Buy
FONR$16.07N/AN/A
XGN$4.19N/AN/A
BNR$6.04N/AN/A

23andme Holding Co Stock Forecast FAQ

What is ME's revenue growth forecast for 2025-2026?

(NASDAQ: ME) 23andme Holding Co's forecast annual revenue growth rate of 15.99% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.46%.

23andme Holding Co's revenue in 2024 is $193,260,000.On average, 1 Wall Street analysts forecast ME's revenue for 2025 to be $5,735,512,141, with the lowest ME revenue forecast at $5,735,512,141, and the highest ME revenue forecast at $5,735,512,141.

In 2026, ME is forecast to generate $6,790,679,220 in revenue, with the lowest revenue forecast at $6,790,679,220 and the highest revenue forecast at $6,790,679,220.

If you're new to stock investing, here's how to buy 23andme Holding Co stock.

What is ME's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: ME) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 10.93%.

What is ME's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: ME) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.